Saturday 17 October 2026
Export ELOX’s income statement to Excel — free account
Senesco Technologies Inc.
ELOX Healthcare Biotechnology
Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
13.03
0.67
−4.89%
Follow ELOX
Senesco Technologies Inc. (ELOX) P/E ratio
Senesco Technologies Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2015 | 0.0× | — |
| Sep 2015 | 0.0× | — |
| Mar 2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GUTS Fractyl Health, Inc. compare | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| ELOX Senesco Technologies Inc. | n/m |
| ALPS Alps Group Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| RNXT RenovoRx, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)